Fundraising Fox
/Companies
Sign in

Shape Therapeutics

Founded 2018 · 32 employees on LinkedIn · 5 known investors

Find your way into Shape Therapeutics

Sign up to see every warm intro you have to Shape Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Shape Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

ShapeTX develops programmable RNA medicines by combining artificial intelligence with RNA technology to address genetic causes of disease.

AI & Machine LearningBiotechDeep Tech

Founders & leadership

Shape Therapeutics was founded in 2018 by Josef von Rickenbach, PhD.

JVJosef von Rickenbach, PhD
Josef von Rickenbach, PhDCo-Founder

Investors · 5

Decheng Capitallisted by Decheng CapitalMenlo Park

How we know: Decheng Capital's portfolio page · funding news · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Mission Biocapitallisted by Mission BiocapitalSan Francisco · $500K

How we know: Mission Biocapital's portfolio page · the VCSheet dataset · Not right? Tell us

Highbury HoldingsreportedSeattle · $100K – $10M

How we know: a partner's Signal profile · Not right? Tell us

Also in the syndicate · 1

CureDuchenne Ventures

Funding

SEC filings, press & company announcements

$35.5M disclosed across 1 of 2 rounds · 2019–2021

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 2

Aro BiotherapeuticsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Stoke TherapeuticsStoke Therapeutics develops RNA-based antisense oligonucleotides to treat severe genetic diseases by restoring protein expression through its TANGO platform, with a lead program in late-stage clinical development for Dravet syndrome and additional programs targeting other genetic disorders of the central nervous system and eye.

Companies working in the same space as Shape Therapeutics.

In the news

Shape Therapeutics Secures $112 Million in Series B Financing to Advance Breakthrough RNA Technology Platforms to Democratize Gene Therapyglobenewswire.com · Jul 2021

Frequently asked questions

What does Shape Therapeutics do?
ShapeTX develops programmable RNA medicines by combining artificial intelligence with RNA technology to address genetic causes of disease.
Who founded Shape Therapeutics?
Shape Therapeutics was founded by Josef von Rickenbach, PhD in 2018.
Who are Shape Therapeutics's investors?
Shape Therapeutics's investors include New Enterprise Associates (NEA), Decheng Capital, Mission Biocapital, Highbury Holdings.
How much funding has Shape Therapeutics raised?
Shape Therapeutics has disclosed $35.5M raised across 1 of its 2 known rounds.